BCL2 and breast carcinoma: YTHDF1 enhances the translation of m6A‐modified Bcl‐2; this leads to the upregulation of this antiapoptotic protein in breast cancer cells and confers them with radioresistance.[123] The m6A eraser, FTO, promotes radioresistance in nasopharyngeal carcinoma (NPC) cells through repression of radiation‐induced ferroptosis.